Nav: Home

Highest out-of-pocket cancer spending for Medicare patients without supplement

November 23, 2016

Which Medicare beneficiaries shoulder the highest out-of-pocket costs after a cancer diagnosis? The answer is those beneficiaries without supplemental insurance, according to a new article published online by JAMA Oncology.

Ensuring the financial security of elderly patients with cancer requires an understanding of which patients experience high out-of-pocket costs and which services contribute to these costs.

Amol K. Narang, M.D., of the Johns Hopkins School of Medicine, Baltimore, and colleagues analyzed survey data for 18,166 Medicare beneficiaries who participated in waves of the Health and Retirement Study, a nationally representative survey of U.S. adults older than 50, from 2002 through 2012. During the study period, 1,409 participants (7.8 percent) were diagnosed with cancer; their median age was 73 and almost 54 percent were male.

Average annual out-of-pocket expenses for all Health and Retirement Study participants were $3,737. A new diagnosis of cancer or a common chronic noncancer condition was associated with increased odds of incurring higher costs, according to the report.

The type, or lack, of supplementary insurance was associated with average annual out-of-pocket costs incurred after a cancer diagnosis, the authors report. Those survey participants with private supplemental insurance, without supplemental insurance or with Medicare benefits through an HMO all had increased odds of higher out-of-pocket costs compared with beneficiaries with Medicaid or Veterans Health Administration coverage.

The average annual out-of-pocket costs following cancer diagnosis for Medicare beneficiaries were $2,116 with Medicaid coverage; $2,367 with Veterans Health Administration coverage; $5,492 with employer-sponsored insurance; $5,670 with Medigap; $5,976 with a Medicare HMO; and $8,115 with traditional fee-for-service Medicare with no supplementary coverage, the authors report.

Hospitalizations were the primary reason for higher out-of-pocket costs, the report notes.

Medicare beneficiaries with a new cancer diagnosis and Medicare alone had average out-of-pocket costs that were almost 24 percent of their household income. In addition, about 10 percent of beneficiaries had out-of-pocket costs that topped 63 percent of their total household income, according to the article.

Limitations of the study include that out-of-pocket expenditures were self-reported by patients.

"Proposals for Medicare reform that restructure the design of benefits for hospital services and incorporate an OOP [out-of-pocket] maximum may help alleviate the risk of financial burden for future beneficiaries, as can interventions that reduce hospitalizations in this population," the study concludes.
-end-
(JAMA Oncol. Published online November 23, 2016. doi:10.1001/jamaoncol.2016.4865; available pre-embargo at the For The Media website.)

Editor's Note: The article contains funding/support disclosures. Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, funding and support, etc.

The JAMA Network Journals

Related Cancer Articles:

Radiotherapy for invasive breast cancer increases the risk of second primary lung cancer
East Asian female breast cancer patients receiving radiotherapy have a higher risk of developing second primary lung cancer.
Cancer genomics continued: Triple negative breast cancer and cancer immunotherapy
Continuing PLOS Medicine's special issue on cancer genomics, Christos Hatzis of Yale University, New Haven, Conn., USA and colleagues describe a new subtype of triple negative breast cancer that may be more amenable to treatment than other cases of this difficult-to-treat disease.
Metabolite that promotes cancer cell transformation and colorectal cancer spread identified
Osaka University researchers revealed that the metabolite D-2-hydroxyglurate (D-2HG) promotes epithelial-mesenchymal transition of colorectal cancer cells, leading them to develop features of lower adherence to neighboring cells, increased invasiveness, and greater likelihood of metastatic spread.
UH Cancer Center researcher finds new driver of an aggressive form of brain cancer
University of Hawai'i Cancer Center researchers have identified an essential driver of tumor cell invasion in glioblastoma, the most aggressive form of brain cancer that can occur at any age.
UH Cancer Center researchers develop algorithm to find precise cancer treatments
University of Hawai'i Cancer Center researchers developed a computational algorithm to analyze 'Big Data' obtained from tumor samples to better understand and treat cancer.
New analytical technology to quantify anti-cancer drugs inside cancer cells
University of Oklahoma researchers will apply a new analytical technology that could ultimately provide a powerful tool for improved treatment of cancer patients in Oklahoma and beyond.
Radiotherapy for lung cancer patients is linked to increased risk of non-cancer deaths
Researchers have found that treating patients who have early stage non-small cell lung cancer with a type of radiotherapy called stereotactic body radiation therapy is associated with a small but increased risk of death from causes other than cancer.
Cancer expert says public health and prevention measures are key to defeating cancer
Is investment in research to develop new treatments the best approach to controlling cancer?
UI Cancer Center, Governors State to address cancer disparities in south suburbs
The University of Illinois Cancer Center and Governors State University have received a joint four-year, $1.5 million grant from the National Cancer Institute to help both institutions conduct community-based research to reduce cancer-related health disparities in Chicago's south suburbs.
Leading cancer research organizations to host international cancer immunotherapy conference
The Cancer Research Institute, the Association for Cancer Immunotherapy, the European Academy of Tumor Immunology, and the American Association for Cancer Research will join forces to sponsor the first International Cancer Immunotherapy Conference at the Sheraton New York Times Square Hotel in New York, Sept.

Related Cancer Reading:

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Climate Crisis
There's no greater threat to humanity than climate change. What can we do to stop the worst consequences? This hour, TED speakers explore how we can save our planet and whether we can do it in time. Guests include climate activist Greta Thunberg, chemical engineer Jennifer Wilcox, research scientist Sean Davis, food innovator Bruce Friedrich, and psychologist Per Espen Stoknes.
Now Playing: Science for the People

#527 Honey I CRISPR'd the Kids
This week we're coming to you from Awesome Con in Washington, D.C. There, host Bethany Brookshire led a panel of three amazing guests to talk about the promise and perils of CRISPR, and what happens now that CRISPR babies have (maybe?) been born. Featuring science writer Tina Saey, molecular biologist Anne Simon, and bioethicist Alan Regenberg. A Nobel Prize winner argues banning CRISPR babies won’t work Geneticists push for a 5-year global ban on gene-edited babies A CRISPR spin-off causes unintended typos in DNA News of the first gene-edited babies ignited a firestorm The researcher who created CRISPR twins defends...